The Global Non-narcotic analgesics market is estimated to grow at a significant CAGR during the forecast period. Non-opioid analgesics are drugs used to relieve pain; however, because most opioid drugs are misused at some point by patients or other people for non-medical purposes, the use of opioid drugs is suggested to be lowered by many healthcare professionals. Non-narcotic analgesics are pain and inflammation-controlling drugs. A non-narcotic drug is one that has antipyretic, analgesic, and anti-inflammatory properties. Non-narcotic analgesics have no effect on opioid receptors. Some of these drugs can be used during surgery to decrease post-operative pain, and reduce the need for narcotics. 

The rising incidence of chronic diseases such as cancer, where different therapies such as chemotherapy are to responsible for pain, is expected to fuel the expansion of the non-opioid analgesics market. The rising number of surgeries is expected to increase the prevalence of post-operative pain, driving the expansion of the non-opioid analgesics market. The growing number of persons suffering neuropathic pain is expected to fuel the expansion of the non-opioid analgesics industry. According to NCBI, Non-narcotic analgesics are effectiveness for a wide spectrum of pain and inflammatory disorders, non-opioid analgesics are among the most commonly used medicines. Over 172 million prescriptions for cyclooxygenase (COX) inhibitors (both selective and non-selective) were issued in the United States alone.

In June 2019, Ironwood Pharmaceuticals and Allergan started treating patients in a Phase II Clinical Trial of MD-7246 in individuals with irritable bowel syndrome and diarrhoea (IBS-D). The drug is being tested as an oral, intestinal, non-opioid pain reliever for individuals with abdominal pain caused by gastrointestinal disorders.

In June 2018, Sandoz Canada announced a collaboration with Tilray, a Health Canada-licensed medical cannabis producer, to become the first Canadian pharmaceutical firm to enter the medical cannabis sector.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment covered 

o By Type

o By Application

• Region covered

o Global

• Competitive Landscape-  Akron, Inc., BioDelivery Sciences International, Inc., Endo Pharmaceuticals., GlaxoSmithKline PLC., Novartis AG., Pfizer., Sanofi S.A, and Teva Pharmaceuticals., among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Market Segmentation

Global non-narcotic analgesics market is segmented by Type

o Non Steroid Anti - inflammatory Drug

o Steroid Anti - inflammatory Drug

Global non-narcotic analgesics market is segmented by Application

o Hospital

o Medical Center

o Others

Global non-narcotic analgesics market is segmented by Region